Zhejiang Shengda Bio-Pharm Co., Ltd. (SHA:603079)
China · Delayed Price · Currency is CNY 20.16
-0.08 (-0.40%)
Feb 4, 2026, 3:00 PM CST
SHA:603079 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 61.08 | 29.42 | -54.06 | 31.48 | 75.76 | 197.44 |
Depreciation & Amortization | 74.57 | 74.57 | 72.61 | 68.25 | 71.32 | 69.72 |
Other Amortization | 5.22 | 5.22 | 5.31 | 4.78 | 5.91 | 4.49 |
Loss (Gain) From Sale of Assets | -0.15 | -0.15 | -0.2 | -0.09 | -0 | 0.01 |
Asset Writedown & Restructuring Costs | 0.29 | 0.29 | 12.21 | 0.1 | 1.52 | 1.02 |
Loss (Gain) From Sale of Investments | -1.45 | -1.45 | -0.41 | -11.27 | -21.55 | -1.32 |
Provision & Write-off of Bad Debts | 5.46 | 5.46 | 3.16 | 0.46 | 0.9 | -0.38 |
Other Operating Activities | -28.19 | 17.08 | 39 | 4.92 | 13.64 | 32.14 |
Change in Accounts Receivable | -45.29 | -45.29 | 36.49 | 10.76 | 250.69 | -15.73 |
Change in Inventory | 19.37 | 19.37 | 23.38 | -87.93 | -63.05 | -6.59 |
Change in Accounts Payable | 40.38 | 40.38 | -74.41 | 20.34 | -261.27 | 49.15 |
Change in Other Net Operating Assets | 2.7 | 2.7 | 1.02 | - | - | - |
Operating Cash Flow | 134.27 | 147.88 | 64.42 | 40.72 | 74.46 | 333.2 |
Operating Cash Flow Growth | 3.02% | 129.55% | 58.22% | -45.32% | -77.65% | 469.05% |
Capital Expenditures | -144.63 | -169.85 | -245.93 | -63.26 | -99.96 | -85.15 |
Sale of Property, Plant & Equipment | 1.35 | 1.31 | 0.73 | 0.53 | 0.93 | 0.74 |
Cash Acquisitions | - | - | -2.87 | -7 | - | - |
Investment in Securities | 65.74 | -15.83 | 7.06 | -30 | 80 | -40.2 |
Other Investing Activities | -1.69 | - | -0.51 | 11.39 | 21.57 | 2.46 |
Investing Cash Flow | -79.24 | -184.37 | -241.52 | -88.33 | 2.55 | -122.16 |
Short-Term Debt Issued | - | - | - | 2.4 | 357.91 | 307 |
Long-Term Debt Issued | - | 153 | 237.9 | 92.53 | - | - |
Total Debt Issued | 144.5 | 153 | 237.9 | 94.93 | 357.91 | 307 |
Short-Term Debt Repaid | - | - | - | -0.72 | -314.64 | -325.26 |
Long-Term Debt Repaid | - | -130.81 | -36.16 | -223.6 | -0.52 | - |
Total Debt Repaid | -79.61 | -130.81 | -36.16 | -224.32 | -315.16 | -325.26 |
Net Debt Issued (Repaid) | 64.89 | 22.19 | 201.74 | -129.39 | 42.75 | -18.26 |
Issuance of Common Stock | 264.53 | - | - | - | - | - |
Repurchase of Common Stock | -13.11 | -13.11 | -8.97 | - | - | - |
Common Dividends Paid | -7.46 | -18.07 | -14.19 | -27.43 | -65.47 | -18.81 |
Other Financing Activities | 11.51 | -0.35 | -1.61 | -0.06 | - | -15 |
Financing Cash Flow | 320.36 | -9.35 | 176.98 | -156.88 | -22.72 | -52.07 |
Foreign Exchange Rate Adjustments | 1.06 | 3.48 | 2.63 | 17.83 | -6.67 | -17.91 |
Net Cash Flow | 376.45 | -42.36 | 2.51 | -186.67 | 47.62 | 141.07 |
Free Cash Flow | -10.36 | -21.97 | -181.51 | -22.54 | -25.5 | 248.05 |
Free Cash Flow Margin | -1.23% | -2.66% | -24.95% | -3.05% | -3.23% | 28.60% |
Free Cash Flow Per Share | -0.06 | -0.13 | -1.07 | -0.13 | -0.15 | 1.47 |
Cash Interest Paid | - | - | - | 0.06 | - | - |
Cash Income Tax Paid | 19.76 | 13.63 | 9.97 | -13.4 | 10.52 | 12.46 |
Levered Free Cash Flow | 30.63 | -46.97 | -174.64 | -56.43 | -55.79 | 130.63 |
Unlevered Free Cash Flow | 31.78 | -45.67 | -173.68 | -53.58 | -52.19 | 133.54 |
Change in Working Capital | 17.43 | 17.43 | -13.2 | -57.91 | -73.03 | 30.08 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.